Bulletin

Investor Alert

New York Markets Close in:

ADC Therapeutics S.A.

NYS: ADCT

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

ADC Therapeutics S.A.

Countdown to close

ADCT

/zigman2/quotes/214411413/composite

32.65

Change

-0.35 -1.06%

Volume

Volume 164,728

Jan 15, 2021, 3:40 p.m.

Real time quotes

/zigman2/quotes/214411413/composite

Previous close

$ 33.00

$ 32.65

Change

-0.35 -1.06%

Day low

Day high

$32.13

$34.45

Open: 33.26

52 week low

52 week high

$25.11

$56.59

Market cap

$2.53B

Average volume

240,867

P/E ratio

N/A

Rev. per Employee

$18,425

EPS

-3.97

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/adct

MarketWatch News on ADCT

ADC Therapeutics started at hold with $42 stock price target at Stifel Nicolaus

8:00 a.m. Dec. 3, 2020

- Tomi Kilgore
ADC Therapeutics stock soars 56% in trading debut

11:05 a.m. May 15, 2020

- Ciara Linnane
ADC Therapeutics stock soars 52% in trading debut

11:02 a.m. May 15, 2020

- Ciara Linnane
ADC Therapeutics prices IPO at $19 a share, above the price range

5:13 a.m. May 15, 2020

- Ciara Linnane
ADC Therapeutics sets IPO terms, to be valued at up to $1 billion

5:56 a.m. May 14, 2020

- Tomi Kilgore
ADC Therapeutics sets IPO terms to raise up to $185.3 million

5:48 a.m. May 14, 2020

- Tomi Kilgore
ADC Therapeutics to offer 8.1 million shares in planned IPO, priced at $23 to $26 each

6:17 a.m. Sept. 23, 2019

- Ciara Linnane
ADC Therapeutics sets IPO terms, to offer 8.1 mln shares priced at $23 to $26 each

6:13 a.m. Sept. 23, 2019

- Ciara Linnane

/news/nonmarketwatch/company/us/adct

Other News on ADCT

ADC Therapeutics initiates expanded access program for loncastuximab tesirine in the U.S.

10:35 a.m. Jan. 7, 2021

- Seeking Alpha
Week In Review: Week's China Life Science Investments Total $800 Million

3:01 p.m. Dec. 20, 2020

- Seeking Alpha
ADC Therapeutics forms strategic JV with Overland Pharma

11:06 a.m. Dec. 15, 2020

- Seeking Alpha
ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures

9:00 a.m. Dec. 15, 2020

- CNW Group
ADC Therapeutics, Overland Pharma inks pact for four cancer candidates in China

7:37 a.m. Dec. 14, 2020

- Seeking Alpha
ADC Therapeutics defended by BofA after ASH presentation

11:14 a.m. Dec. 7, 2020

- Seeking Alpha
Wall Street Breakfast: The Week Ahead

6:41 a.m. Nov. 22, 2020

- Seeking Alpha
Stocks To Watch: Eyes On Best Buy, Vaccines And Holiday Cheer

8:41 a.m. Nov. 21, 2020

- Seeking Alpha
FDA accepts ADC Therapeutics' lonca US application for a type of blood cancer

7:26 a.m. Nov. 20, 2020

- Seeking Alpha
ADC Therapeutics' (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call Transcript

2:17 p.m. Nov. 12, 2020

- Seeking Alpha
Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?

8:46 a.m. Nov. 11, 2020

- Zacks.com
Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?

9:48 a.m. Nov. 9, 2020

- Zacks.com
Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates

11:38 a.m. Nov. 5, 2020

- Zacks.com
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

11:35 a.m. Nov. 5, 2020

- Zacks.com
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected

10:29 a.m. Nov. 3, 2020

- Zacks.com
Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y

10:26 a.m. Nov. 3, 2020

- Zacks.com
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales

10:14 a.m. Nov. 3, 2020

- Zacks.com
Early-stage study commences on ADC antibody-drug conjugate in solid tumors

8:26 a.m. Nov. 3, 2020

- Seeking Alpha
ADC Therapeutics amends Genmab deal to advance antibody-drug conjugate over finish line

7:41 a.m. Oct. 30, 2020

- Seeking Alpha
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates

10:32 a.m. Oct. 28, 2020

- Zacks.com
Loading more headlines...

/news/pressrelease/company/us/adct

Press Releases on ADCT

ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.

7:15 a.m. Jan. 7, 2021

- BusinessWire - BZX
Wireless and Mobile Backhaul Equipment Market Size and Business Trends 2021: Global Growth Factors, Product Scope, Company Profiles, Future Outlook by Covid-19 Impact and Development Status till 2026

2:13 a.m. Jan. 7, 2021

- The Express Wire
ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event

7:15 a.m. Jan. 4, 2021

- BusinessWire - BZX
Digital Subscriber Line (DSL) Network Equipment Market Present Situation and Potential Growth with Forecast Report 2026

2:08 a.m. Dec. 24, 2020

- News AIM
Digital Subscriber Line (DSL) Network Equipment Market 2018 Growth Opportunities By Top Manufactures, and Investment Feasibility 2026

2:07 a.m. Dec. 24, 2020

- News AIM
CMTS-QAM Market by Organization Size 2021 | Top Manufacturers Analysis by Geographical Trends, Demand Status, Business Growth, and End User Analysis, Outlook till 2026

12:05 a.m. Dec. 16, 2020

- The Express Wire
ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures

9:00 a.m. Dec. 15, 2020

- PR Newswire - PRF
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore

7:00 a.m. Dec. 14, 2020

- BusinessWire - BZX
CMTS-QAM Market 2021 Size, Share and Outlook 2026: COVID-19 Market Scenario, Growth Factors, Opportunity, Sales Revenue, Regional Analysis by Industry Research Biz

12:38 a.m. Dec. 9, 2020

- The Express Wire
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting

7:00 a.m. Dec. 7, 2020

- BusinessWire - BZX
ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting

7:15 a.m. Nov. 30, 2020

- BusinessWire - BZX
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

7:00 a.m. Nov. 20, 2020

- BusinessWire - BZX
ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights

7:00 a.m. Nov. 12, 2020

- BusinessWire - BZX
ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

7:15 a.m. Nov. 10, 2020

- BusinessWire - BZX
CMTS-QAM Market Global Industry Growth, Historical Analysis, Size, Trends, Emerging Factors, Requests, Key Players, Emerging Technologies, and Industry Potential Forecast to 2026

1:58 a.m. Nov. 10, 2020

- The Express Wire
ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020

7:15 a.m. Nov. 5, 2020

- BusinessWire - BZX
ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting

11:00 a.m. Nov. 4, 2020

- BusinessWire - BZX
ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors

7:15 a.m. Nov. 3, 2020

- BusinessWire - BZX
CMTS-QAM Market Share, Size 2020 Business Revenue, Future Growth, Trends Plans, Top Key Players, Business Opportunities, Industry Analysis by Forecast to 2025 Research Reports World

11:52 p.m. Nov. 2, 2020

- The Express Wire
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

6:15 a.m. Oct. 30, 2020

- BusinessWire - BZX
Loading more headlines...

Rates »

Mortgage Equity Savings Auto

National averages from Bankrate.com

Trending Tickers

/quotes/zigman/17636479/composite VUZI+15.60%
/quotes/zigman/237947/composite JCP-5.83%
/quotes/zigman/59392505/composite NUGT-2.93%
/quotes/zigman/59386294/composite JNUG-5.94%
/quotes/zigman/65801738/composite TLT+1.11%

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

ADC Therapeutics S.A.

MarketWatch News on ADCT

Other News on ADCT

Press Releases on ADCT

Rates »

Latest News

dow

nasdaq

s&p 500

Kiosk